DNA-In? Transfection Reagent

A Universal Transfection Reagent for DNA Delivery

DNA-In?  is the newest generation transfection product developed by the lead members of the scientific team that invented the Lipofectamine? and Lipofectamine? 2000.  DNA-In?  is a novel cationic transfection reagent which balances high transfection and expression levels with low toxicity.  DNA-In?  works on a very broad range of adherent cells including most passaged cell lines and many primary cells.

• Product sheet

• Features

• Fast, simple, easy-to-follow protocol
  

• One-step process: simply add DNA-In?  Reagent to diluted DNA, incubate 10 minutes, and add to pre-plated cells
  

• Minimal toxicity - no need to replace medium after transfection
  

DNA-In?  Transfection Reagent  "Quick-Start Protocol"

Superior Transfection Efficiency

During its development and validation process, DNA-In?  Reagent underwent extensive testing in many primary and cultured cells. In a head-to-head comparison study, DNA-In? consistently outperformed the Lipofectamine? 2000 transfection reagent.

Cells were transfected with a plasmid, containing EmeraldGFP behind an EF1α promoter, with either DNA-In?  or Lipofectamine?2000, at several different lipid:DNA ratios and examined ~44 hours post-transfection. Representative images of the best conditions for each transfection reagent are shown.

Low Cell Toxicity 

DNA-In?  has a significantly lower cell toxicity compared to traditional transfection reagents such as Lipofectamine?  and Lipofectamine?  2000.  In the many cell lines tested, DNA-In? shows a broad range of effective dosage while maintaining minimal cell toxicity.  This low cell toxicity allows a larger dosage and time window for optimized transfection results.

The following charts show side-by-side comparisons of DNA-In?  and Lipofectamine? 2000 (LF2K) in commonly used cell lines and primary cells:

In 293 cells, DNA-In?  maintains high cell viability throughout the tested dosage range, while LF2K has a significant cell toxicity issue when used in dosages over 3μl.

In A549 cells, DNA-In?  has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.

In human fibroblast cells, DNA-In?  has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.

In HeLa cells, DNA-In has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.

In HepG2 cells, DNA-In has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.

In MCF7 cells, DNA-In has a significantly higher transfection efficiency and a lower cell toxicity while LF2K transfection efficiency is lower and is toxic when used in dosages higher than 2μl.